| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
50 |
| Employees |
111 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-342 |
| Cash Flow (TTM) (Millions $) |
-136 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
Turning Point Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel targeted cancer therapeutics for treating solid tumor malignancies. Founded in 2013 and headquartered in California, USA, the company is focused on developing small molecule inhibitors that selectively target specific genetic alterations and oncogenic pathways that are associated with cancer progression.
Turning Point Therapeutics is committed to transforming the way cancer is treated by developing drugs that are highly effective, safe, and well-tolerated. The company's lead drug candidate, repotrectinib, is currently being evaluated in multiple ongoing phase 1/2 clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and others.
In addition to repotrectinib, the company has a robust pipeline of other drug candidates that target various oncogenic pathways, including ALK, ROS1, and TRK fusion genes, which are frequently found in a range of cancer types. Turning Point Therapeutics aims to develop new drugs with improved clinical outcomes for cancer patients, as well as overcome resistance to current therapies.
The company has established collaborations with leading academic institutions, pharmaceutical companies, and contract research organizations (CROs) to advance the development and commercialization of its drugs. Turning Point Therapeutics has a highly experienced leadership team with a track record of success in drug development, clinical research, and commercialization.
Overall, Turning Point Therapeutics is a highly innovative biopharmaceutical company that is dedicated to improving the lives of cancer patients by developing targeted cancer therapeutics that address unmet medical needs. With a strong pipeline of drug candidates and a solid management team, the company is well-positioned for continued growth and success in the biopharmaceutical industry.
Company Address: 10628 Science Center Drive San Diego 92121 CA
Company Phone Number: 926-5251 Stock Exchange / Ticker: NASDAQ TPTX
|
%
0.62%